RxDoctor Payments Data

Mandy Brannen, APRN

Psychiatric/Mental Health · El Cajon, CANPI 1891205159

Payments from drug & device makers

$1,121in general payments, 2019–2025

Across 51 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$434
  • Alkermes, Inc.$143
  • Teva Pharmaceuticals USA, Inc.$123
  • Lundbeck LLC$105
  • Sunovion Pharmaceuticals Inc.$97
  • Otsuka America Pharmaceutical, Inc.$90
  • plus $128 from 4 others

What the payments were for

  • Food & beverage$1,121100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,121 in reported general payments places this provider in the 70th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$153,419
Medicare patients
291
Services billed
2,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl158$233,331
IngrezzaValbenazine Tosylate19$153,773
Invega SustennaPaliperidone Palmitate42$129,666
Abilify MaintenaAripiprazole23$65,229
Chlorpromazine Hcl146$44,115
Naltrexone Hcl378$35,103
Aripiprazole406$34,110
LybalviOlanzapine/Samidorphan Malate21$33,317
Quetiapine Fumarate1,069$30,419
Divalproex Sodium397$24,264
Risperidone1,022$19,326
RexultiBrexpiprazole12$19,042
Olanzapine786$18,630
ZyprexaOlanzapine16$18,206
Buspirone Hcl530$16,698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$434$233,331158 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$90$84,27135 claims
Alkermes, Inc.Lybalvi$143$33,31721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in El Cajon

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →